FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233459083> ?p ?o ?g. }

• W4233459083 endingPage "267" @default.
• W4233459083 startingPage "267" @default.
• W4233459083 abstract "Abstract Abstract 267 Introduction Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by platelet, monocyte, and endothelial cell-activating antibodies (Abs) against ultralarge complexes of platelet factor 4 (PF4) and heparin. Laboratory testing plays a key role in the diagnosis of HIT, but is associated with important shortcomings. Immunoassays such as the PF4/heparin ELISA frequently yield false-positive results due to their inability to discriminate cellular activating-Abs from their non-pathogenic counterparts. Functional assays such as the 14C-serotonin release assay (SRA) are more specific, but are unfeasible for most clinical laboratories due to the requirement for radioisotope and fresh platelets from reactive donors. KKO is a monoclonal Ab that causes a HIT-like thrombocytopenic disorder in a mouse model. Binding of KKO to immobilized PF4/heparin is inhibited by human HIT plasma, but not by plasma from patients with non-pathogenic anti-PF4/heparin Abs.1 We exploited this property of KKO to develop a KKO-inhibition (KKO-I) ELISA to detect platelet-activating Abs. We recently described a system to measure cell activation by HIT Abs: DT40 (chicken B lymphocyte) cells transfected with human FcgRIIa coupled to a luciferase reporter.2 We hypothesized that this system (DT40-luc) could be used to identify cell-activating anti-PF4/heparin Abs without need for donor platelets or radioactivity. Here we describe the KKO-I and DT40-luc assays and compare their performance to two commercially available immunoassays and the SRA in samples from 58 patients with suspected HIT and circulating anti-PF4/heparin Abs. Methods Patient samples consecutively referred to a clinical coagulation laboratory for HIT laboratory testing that tested positive by polyspecific anti-PF4/heparin ELISA were included. In addition to the polyspecific ELISA, citrated plasma samples from all patients were tested by an IgG-specific PF4/heparin ELISA, an in-house SRA, and the investigational KKO-I and DT40-luc assays. A 4Ts score to estimate the clinical likelihood of HIT was determined for each subject. The investigator performing 4Ts scoring was blinded to the results of HIT laboratory assays. Investigators performing the KKO-I and DT40-luc assays were blinded to the 4Ts score and the results of the SRA and anti-PF4/heparin ELISA. The KKO-I and DT40-luc assays were performed as previously described.1,2 HIT was defined as the combination of an intermediate or high probability 4Ts score (≥4) and a positive SRA. The performance of each assay with respect to this reference standard was evaluated by receiver-operating characteristic (ROC) analysis. Areas under the ROC curves (AUCs) were calculated and compared using the Delong method for correlated samples. Results Fifty-eight subjects were enrolled, 21 of whom met prespecified criteria for HIT. There were no significant differences in demographic characteristics between the 21 HIT-positive and 37 HIT-negative subjects. The ability of the polyspecific ELISA, IgG-specific ELISA, KKO-I, and DT40-luc assay to discriminate HIT-positive from HIT-negative subjects is shown in Figure 1. HIT-positive plasma showed significantly greater mean inhibition of KKO binding than HIT-negative plasma (70.1%, 95% CI 64.8–75.4 vs. 40.4%, 33.5–47.4, p<0.0001) (Figure 1C). Plasma from HIT-positive subjects also induced significantly greater luciferase activity (3.14, 2.25–4.03 vs. 0.96, 0.85–1.07, p<0.0001) in the DT40-luc assay (Figure 1D). ROC curves for each assay are shown in Figure 2. The AUC for KKO-I (0.92, 0.85–1.00) was significantly greater than the AUC for the polyspecific (0.82, 0.70–0.95) and IgG-specific (0.76, 0.62–0.90) ELISAs (p<0.05 for both comparisons). The AUC for DT40-luc (0.89, 0.79–0.99) was significantly greater than the AUC for the IgG-specific (p=0.046), but not the polyspecific ELISA (p=0.28). Conclusion KKO-I and DT40-luc showed better discrimination than commercially available ELISAs in a small cohort of patients with suspected HIT and anti-PF4/heparin Abs. These assays are simple to perform, do not require donor platelets or radioactivity, and hold promise for improving the specificity and feasibility of HIT laboratory testing. Further evaluation in a larger cohort of patients is required. Disclosures: Cuker: Baxter: Consultancy, Research Funding; Bayer: Consultancy; Canyon: Consultancy; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Stago: Research Funding. Arepally:Teva Pharmaceuticals: Research Funding. Cines:Amgen: Consultancy; GSK: Consultancy; Eisai: Consultancy; T2 Biosystems: Research Funding." @default.
• W4233459083 created "2022-05-12" @default.
• W4233459083 creator A5003106879 @default.
• W4233459083 creator A5014530935 @default.
• W4233459083 creator A5026395590 @default.
• W4233459083 creator A5040851400 @default.
• W4233459083 creator A5041880715 @default.
• W4233459083 creator A5046176849 @default.
• W4233459083 creator A5070714730 @default.
• W4233459083 creator A5075042066 @default.
• W4233459083 creator A5076619166 @default.
• W4233459083 creator A5077478635 @default.
• W4233459083 creator A5017683610 @default.
• W4233459083 date "2012-11-16" @default.
• W4233459083 modified "2023-10-16" @default.
• W4233459083 title "Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia" @default.
• W4233459083 doi "https://doi.org/10.1182/blood.v120.21.267.267" @default.
• W4233459083 hasPublicationYear "2012" @default.
• W4233459083 type Work @default.
• W4233459083 citedByCount "1" @default.
• W4233459083 countsByYear W42334590832014 @default.
• W4233459083 crossrefType "journal-article" @default.
• W4233459083 hasAuthorship W4233459083A5003106879 @default.
• W4233459083 hasAuthorship W4233459083A5014530935 @default.
• W4233459083 hasAuthorship W4233459083A5017683610 @default.
• W4233459083 hasAuthorship W4233459083A5026395590 @default.
• W4233459083 hasAuthorship W4233459083A5040851400 @default.
• W4233459083 hasAuthorship W4233459083A5041880715 @default.
• W4233459083 hasAuthorship W4233459083A5046176849 @default.
• W4233459083 hasAuthorship W4233459083A5070714730 @default.
• W4233459083 hasAuthorship W4233459083A5075042066 @default.
• W4233459083 hasAuthorship W4233459083A5076619166 @default.
• W4233459083 hasAuthorship W4233459083A5077478635 @default.
• W4233459083 hasBestOaLocation W42334590832 @default.
• W4233459083 hasConcept C159654299 @default.
• W4233459083 hasConcept C159973064 @default.
• W4233459083 hasConcept C185592680 @default.
• W4233459083 hasConcept C203014093 @default.
• W4233459083 hasConcept C2776472838 @default.
• W4233459083 hasConcept C2777557582 @default.
• W4233459083 hasConcept C2780420688 @default.
• W4233459083 hasConcept C2781184567 @default.
• W4233459083 hasConcept C3018697912 @default.
• W4233459083 hasConcept C542903549 @default.
• W4233459083 hasConcept C55493867 @default.
• W4233459083 hasConcept C71924100 @default.
• W4233459083 hasConcept C89560881 @default.
• W4233459083 hasConcept C98274493 @default.
• W4233459083 hasConceptScore W4233459083C159654299 @default.
• W4233459083 hasConceptScore W4233459083C159973064 @default.
• W4233459083 hasConceptScore W4233459083C185592680 @default.
• W4233459083 hasConceptScore W4233459083C203014093 @default.
• W4233459083 hasConceptScore W4233459083C2776472838 @default.
• W4233459083 hasConceptScore W4233459083C2777557582 @default.
• W4233459083 hasConceptScore W4233459083C2780420688 @default.
• W4233459083 hasConceptScore W4233459083C2781184567 @default.
• W4233459083 hasConceptScore W4233459083C3018697912 @default.
• W4233459083 hasConceptScore W4233459083C542903549 @default.
• W4233459083 hasConceptScore W4233459083C55493867 @default.
• W4233459083 hasConceptScore W4233459083C71924100 @default.
• W4233459083 hasConceptScore W4233459083C89560881 @default.
• W4233459083 hasConceptScore W4233459083C98274493 @default.
• W4233459083 hasIssue "21" @default.
• W4233459083 hasLocation W42334590831 @default.
• W4233459083 hasLocation W42334590832 @default.
• W4233459083 hasOpenAccess W4233459083 @default.
• W4233459083 hasPrimaryLocation W42334590831 @default.
• W4233459083 hasRelatedWork W1533566370 @default.
• W4233459083 hasRelatedWork W1546557507 @default.
• W4233459083 hasRelatedWork W2023898963 @default.
• W4233459083 hasRelatedWork W2079614982 @default.
• W4233459083 hasRelatedWork W2135344285 @default.
• W4233459083 hasRelatedWork W2587814161 @default.
• W4233459083 hasRelatedWork W2595840678 @default.
• W4233459083 hasRelatedWork W2744474093 @default.
• W4233459083 hasRelatedWork W4210516061 @default.
• W4233459083 hasRelatedWork W4242038659 @default.
• W4233459083 hasVolume "120" @default.
• W4233459083 isParatext "false" @default.
• W4233459083 isRetracted "false" @default.
• W4233459083 workType "article" @default.